NEW YORK – BostonGene today announced a partnership with the National Institutes of Health to offer molecular profiling and therapy recommendations in a cancer study.
The software firm is launching a new study with collaborators at the National Cancer Institute and the National Institute of Allergy and Infectious Disease to analyze the clonal evolution of solid and liquid tumors in patients.